Potential Collaboration

A key to the success of AETIONOMY will be the quality and quantity of data from patients with Alzheimer’s and Parkinson’s disease that we can access.  AETIONOMY is being built on the datasets from the current collaborators and the publically available datasets.  However we know that whilst this is a good starting point there are a lot of high quality datasets that we cannot access.  The aim of AETIONOMY is to develop a comprehensive map of pathophysiological processes causing Alzheimer’s Disease and Parkinson’s Disease and these maps will be publically available to everyone.  These maps will form the basis of the new disease classification which we will be encouraging everyone to validate.  If you have datasets and are willing to collaborate then we would really like you to contact the AETIONOMY project office as we want this project to be as comprehensive as possible and a foundation for Alzheimer’s and Parkinson’s disease research and clinical practice for the biomedical community.

Partners

The structure and size of the project consortium and the proposed project activities have been formulated to ensure a cost effective approach to realising the project objectives. Care has been taken that all activities are well covered, and the amounts are realistically presented.

The following partners participate in the AETIONOMY project:

 

UCB Pharma

 

Belgium

 

Fraunhofer-Gesellschaft e.V.

 

Germany

 

Erasmus Medical Center

 

Netherlands

Universitaetsklinikum Bonn

Germany

 

ICM- Institut du Cerveau et de la Moelle épinière

 

France

Consorci Institut D´Investigacions Biomediques August Pi l Sunyer

Spain

 

Leibniz Universitaet Hannover

 

Germany

 

Pharmacoidea Ltd.

 

Hungary

Luxembourg Centre for Systems Biology

Luxembourg

 

Alzheimer Europe

 

Luxembourg

 

Karolinska Institutet

 

Sweden

Novartis

Switzerland



Sanofi

France

Boehringer Ingelheim

Germany

Institut de Neurosciences des Systèmes

Marseille, France

BARCELONABETA

Barcelona

 

AETIONOMY has 10 academic partners (of which 4 are clinical partners), 2 SMEs and 4 EFPIA partners. The 4 committed partners (UCB; Novartis, SARD & BI), have allocated resources  as well as a substantial financial support  of in-kind contribution over the  entire project. The AETIONOMY project is organised in 5 work packages. Work packages 1, 2, 4 and 5 have been pre-defined in the call text, so that only for WP3 were we free to chose a topic and title which is now called “clinical study”, as this reflects the nature of the clinical validation efforts.

PRECISESADS

Molecular reclassification to find clinically useful biomarkers for systemic autoimmune diseases  

 

EPAD

European Prevention of Alzheimer´s Dementia Consortium

EMIF

European Medical Information Framework 

neuGRID4U

N4U - neuGRID for you expansion of neuGRID services and outreach to new user communities  

VPH-DARE

Virtual Physiological Human:
DementiA Research Enabled by IT  

HBP

Human Brain Project

DPUK

Dementias Platform UK
Medical Research Council